CA3044056A1 - Methods and compositions to detect mutations in plasma using exosomal rna and cell free dna from non-small cell lung cancer patients - Google Patents

Methods and compositions to detect mutations in plasma using exosomal rna and cell free dna from non-small cell lung cancer patients Download PDF

Info

Publication number
CA3044056A1
CA3044056A1 CA3044056A CA3044056A CA3044056A1 CA 3044056 A1 CA3044056 A1 CA 3044056A1 CA 3044056 A CA3044056 A CA 3044056A CA 3044056 A CA3044056 A CA 3044056A CA 3044056 A1 CA3044056 A1 CA 3044056A1
Authority
CA
Canada
Prior art keywords
nucleic acid
nucleic acids
mutation
egfr
exon19
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3044056A
Other languages
English (en)
French (fr)
Inventor
Johan Karl Olov Skog
Elena CASTELLANOS-RIZALDOS
Vasisht TADIGOTLA
Dominik GRIMM
Xuan Zhang
Wei Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exosome Diagnostics Inc
Original Assignee
Exosome Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exosome Diagnostics Inc filed Critical Exosome Diagnostics Inc
Publication of CA3044056A1 publication Critical patent/CA3044056A1/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/6851Quantitative amplification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/16Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA3044056A 2016-11-30 2017-11-17 Methods and compositions to detect mutations in plasma using exosomal rna and cell free dna from non-small cell lung cancer patients Pending CA3044056A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662428059P 2016-11-30 2016-11-30
US62/428,059 2016-11-30
PCT/US2017/062370 WO2018102162A1 (en) 2016-11-30 2017-11-17 Methods and compositions to detect mutations in plasma using exosomal rna and cell free dna from non-small cell lung cancer patients

Publications (1)

Publication Number Publication Date
CA3044056A1 true CA3044056A1 (en) 2018-06-07

Family

ID=60766137

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3044056A Pending CA3044056A1 (en) 2016-11-30 2017-11-17 Methods and compositions to detect mutations in plasma using exosomal rna and cell free dna from non-small cell lung cancer patients

Country Status (7)

Country Link
US (1) US11427864B2 (cg-RX-API-DMAC7.html)
EP (1) EP3548635B1 (cg-RX-API-DMAC7.html)
JP (1) JP7280823B2 (cg-RX-API-DMAC7.html)
CN (1) CN110446790B (cg-RX-API-DMAC7.html)
AU (1) AU2017366813B2 (cg-RX-API-DMAC7.html)
CA (1) CA3044056A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018102162A1 (cg-RX-API-DMAC7.html)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018102162A1 (en) 2016-11-30 2018-06-07 Exosome Diagnostics, Inc. Methods and compositions to detect mutations in plasma using exosomal rna and cell free dna from non-small cell lung cancer patients
WO2019099629A1 (en) * 2017-11-17 2019-05-23 Gen-Probe Incorporated COMPOSITIONS AND METHODS FOR DETECTING C1orf43 NUCLEIC ACID
CN108707671A (zh) * 2018-06-12 2018-10-26 上海浦美生物医药科技有限公司 一种用于血液egfr c797s突变检测的引物探针组合物和试剂盒
CN109207595A (zh) * 2018-10-07 2019-01-15 浙江数问生物技术有限公司 一种人egfr基因t790m突变检测试剂盒及其检测方法
US20220155304A1 (en) * 2019-03-01 2022-05-19 Mercy Bioanalytics, Inc. Systems, compositions, and methods for target entity detection
CN110749734A (zh) * 2019-12-06 2020-02-04 四川大学华西医院 Gtf2i自身抗体检测试剂在制备肺癌筛查试剂盒中的用途
CN111733158B (zh) * 2020-02-11 2022-09-06 昆明医科大学 一种抑制hsa_circ_0003599表达的siRNA及其应用
CN111500640B (zh) * 2020-04-17 2021-09-10 四川省人民医院 Rp疾病模型的构建方法以及培育方法
CN111748624B (zh) * 2020-06-08 2022-11-04 郑州大学第一附属医院 用于预测肝癌是否复发的生物标志物
CN111676290B (zh) * 2020-07-02 2021-03-02 王伟佳 一种急性髓系白血病诱导分化治疗耐药的分子标志物及其应用
CN111690752A (zh) * 2020-07-16 2020-09-22 重庆浦洛通基因医学研究院有限公司 一种检测人类egfr基因突变的试剂盒及其方法
CN112410335B (zh) * 2020-11-03 2022-10-04 安徽大学 一种阻止lactb2表达来抑制非小细胞肺癌增殖生长的应用
CN112501292B (zh) * 2020-11-09 2022-12-02 中国人民解放军海军军医大学 cFAM210A在制备肝癌诊断或术后预测试剂盒以及药物中的应用
CN114480607B (zh) * 2020-11-12 2024-04-30 上海昂朴生物科技有限公司 用于检测gipc1基因5’-utr区域cgg扩增次数的pcr检测试剂盒及应用
CN112375810A (zh) * 2020-11-16 2021-02-19 北京大学人民医院 GnT-II基因下调表达作为肝癌预后标志物中的应用
CN112370527B (zh) * 2020-12-02 2022-11-01 成都医学院第一附属医院 Dnajc19基因作为靶点在制备治疗非小细胞肺癌药物中的应用
CN112481234B (zh) * 2020-12-03 2023-09-22 重庆工业职业技术学院 一种焦磷酸酶突变体合成核酸糖类似物及其应用
CN112795652A (zh) * 2021-02-02 2021-05-14 中国科学院合肥物质科学研究院 环形RNAcircURI1在制备胃癌生物标志物的应用及其试剂盒
US20240301413A1 (en) * 2021-03-11 2024-09-12 The Children's Hospital Of Philadelphia Compositions and methods useful for the treatment of bone marrow failure diseases associated with ribosomopathies
CN113373206A (zh) * 2021-08-03 2021-09-10 远辰生物科技(苏州)有限公司 一种egfr基因突变检测体系及其试剂盒
CN113774135B (zh) * 2021-09-17 2024-03-08 广东省人民医院 一组用于预测高级别浆液性卵巢癌预后的标志物及其应用
CN113549697B (zh) * 2021-09-23 2022-03-01 广州医科大学附属肿瘤医院 一种胃癌热化疗敏感标志物及其应用
CN113913333B (zh) * 2021-10-20 2022-09-02 南京世和基因生物技术股份有限公司 一种肺癌诊断标志物及用途
CN114231529B (zh) * 2021-11-17 2023-08-01 中国科学院昆明动物研究所 一种人pkmyt1ar基因及其应用
CN114934048B (zh) * 2022-02-22 2023-09-26 浙大城市学院 一种用于肿瘤治疗靶点和诊断生物标志物的circMTMR14及试剂盒和应用
EP4491745A1 (en) * 2022-03-08 2025-01-15 Korea Advanced Institute of Science and Technology Pharmaceutical composition comprising setmar inhibitor for preventing or treating cancer
CN114672564B (zh) * 2022-03-31 2025-06-13 郑州颐和医院 Tmod3和/或adsl在非小细胞癌中的应用
CN114592006A (zh) * 2022-04-29 2022-06-07 昆明理工大学 Memo1基因的新用途
CN114839375B (zh) * 2022-05-23 2025-07-25 中国药科大学 与肺癌相关的尿液微囊泡蛋白及其应用
CN114703287B (zh) * 2022-06-06 2022-08-12 江苏省肿瘤医院 CXorf56基因在治疗三阴性乳腺癌中的应用
CN114703288B (zh) * 2022-06-06 2022-09-13 珠海圣美生物诊断技术有限公司 用于扩增EGFR-T790M基因变异的blocker探针、引物组及其应用
CN115896262B (zh) * 2022-07-12 2025-05-30 重庆医科大学附属儿童医院 一种神经嵴疾病的诊断标志物及其应用
CN115877004B (zh) * 2022-08-09 2024-12-20 重庆大学 一种taok3抑制剂以及taok3及其抑制剂在调控天然免疫系统中的应用
CN115948532A (zh) * 2022-08-17 2023-04-11 湖南圣洲生物科技有限公司 基于数字pcr技术的sma检测试剂盒
CN115354079A (zh) * 2022-09-05 2022-11-18 复旦大学附属中山医院 一种用于检测egfr靶向药物治疗适用性的试剂盒
WO2024064814A1 (en) * 2022-09-21 2024-03-28 Zephyr Ai, Inc. Apparatus and methods for determining sensitivity to osimertinib
CN115595372B (zh) * 2022-12-16 2023-03-14 南京世和基因生物技术股份有限公司 一种血浆游离dna来源的甲基化检测方法、肺癌诊断标志物以及试剂盒
CN116240275A (zh) * 2023-03-01 2023-06-09 申联生物医药(上海)股份有限公司 一种哺乳动物通用的rna内参基因及其引物和应用
CN116751873B (zh) * 2023-06-26 2025-04-08 宁夏大学 与牛十字部高相关的snp位点及应用
CN117491636A (zh) * 2023-11-21 2024-02-02 郑州大学 一种用于肺癌诊断的生物标志物及其应用
CN118599905A (zh) * 2024-02-21 2024-09-06 湖北文理学院 Tm9sf1在用于抑制fen1进入细胞核中的应用
CN120392963A (zh) * 2024-03-26 2025-08-01 首都医科大学附属北京胸科医院 一种改善耐药性肺癌患者对egfr-tki抑制剂敏感性的药物
CN118813812B (zh) * 2024-06-26 2025-12-05 中国农业大学 一种与鸡不同周龄胸深相关的snp分子标记及应用
CN118910268B (zh) * 2024-06-26 2025-12-05 中国农业大学 一种与鸡六周龄体重性状相关的snp标记及其应用
CN119709991B (zh) * 2025-02-28 2025-06-24 华中科技大学同济医学院附属同济医院 芳基硫酸酯酶k在制备预防、延缓或治疗慢性阻塞性肺疾病药物中的应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639611A (en) 1988-12-12 1997-06-17 City Of Hope Allele specific polymerase chain reaction
US5219727A (en) 1989-08-21 1993-06-15 Hoffmann-Laroche Inc. Quantitation of nucleic acids using the polymerase chain reaction
CA2218875C (en) 1991-07-23 2000-11-07 The Research Foundation Of State University Of New York Improvements in the in situ pcr
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
US5639606A (en) 1993-04-06 1997-06-17 The University Of Rochester Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5556773A (en) 1993-08-06 1996-09-17 Yourno; Joseph Method and apparatus for nested polymerase chain reaction (PCR) with single closed reaction tubes
EP0954612A2 (en) 1996-11-06 1999-11-10 Sequenom, Inc. Dna diagnostics based on mass spectrometry
US6994960B1 (en) 1997-05-28 2006-02-07 The Walter And Eliza Hall Institute Of Medical Research Nucleic acid diagnostics based on mass spectrometry or mass separation and base specific cleavage
US6004755A (en) 1998-04-07 1999-12-21 Incyte Pharmaceuticals, Inc. Quantitative microarray hybridizaton assays
FR2788780B1 (fr) 1999-01-27 2001-03-30 Ap Cells Inc Procede de preparation de vesicules membranaires
US6277607B1 (en) 1999-05-24 2001-08-21 Sanjay Tyagi High specificity primers, amplification methods and kits
GB9927320D0 (en) 1999-11-18 2000-01-12 Chiron Spa Exosome separation
US6812023B1 (en) 2000-04-27 2004-11-02 Anosys, Inc. Methods of producing membrane vesicles
US6913879B1 (en) 2000-07-10 2005-07-05 Telechem International Inc. Microarray method of genotyping multiple samples at multiple LOCI
US6696271B2 (en) 2001-08-23 2004-02-24 The Regents Of The University Of California Frozen tissue microarray technology for analysis of RNA, DNA, and proteins
WO2003023065A1 (en) 2001-09-06 2003-03-20 Syngenta Participations Ag Dna methylation patterns
EP2339025B1 (en) 2002-06-26 2013-10-09 Cold Spring Harbor Laboratory Methods for determining the methylation profiles
WO2004020667A1 (en) 2002-09-02 2004-03-11 Pamgene B.V. Novel integrated microarray analysis
US7141371B2 (en) 2002-09-06 2006-11-28 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Methods for detecting and localizing DNA mutations by microarray
WO2006113590A2 (en) 2005-04-15 2006-10-26 Cedars-Sinai Medical Center Flow-cytometric heteroduplex analysis for detection of genetic alterations
AU2007293280A1 (en) * 2006-09-07 2008-03-13 Astrazeneca Ab Method for evaluating patients for treatment with drugs targeting RET receptor tyrosine kinase
CN101622349A (zh) * 2006-12-08 2010-01-06 奥斯瑞根公司 作为治疗性干预靶标的miR-21调节的基因和途径
US20090104120A1 (en) * 2007-09-25 2009-04-23 The Regents Of The University Of Michigan Dlx1 cancer markers
KR101970908B1 (ko) * 2008-02-01 2019-04-19 더 제너럴 하스피탈 코포레이션 의학적 질환 및 병태의 진단, 예후, 및 치료에 있어서 미세소포체의 용도
US20160041153A1 (en) * 2008-11-12 2016-02-11 Kirk Brown Biomarker compositions and markers
WO2012135844A2 (en) * 2011-04-01 2012-10-04 Cornell University Circulating exosomes as diagnostic/prognostic indicators and therapeutic targets of melanoma and other cancers
CN105026911B (zh) 2013-01-03 2019-01-22 外来体诊断公司 用于分离微囊泡的方法
EP4253558B1 (en) * 2013-03-15 2025-07-02 The Board of Trustees of the Leland Stanford Junior University Identification and use of circulating nucleic acid tumor markers
WO2014193999A2 (en) * 2013-05-28 2014-12-04 Caris Science, Inc. Biomarker methods and compositions
US20150132256A1 (en) * 2013-10-19 2015-05-14 Trovagene, Inc. Detecting and monitoring mutations in histiocytosis
US10519502B2 (en) * 2013-10-31 2019-12-31 The Children's Hospital Of Philadelphia Mitochondrial disease genetic diagnostics
EP3125907A4 (en) * 2014-04-01 2017-11-29 Cornell University Use of double-stranded dna in exosomes: a novel biomarker in cancer detection
CA3084920C (en) 2014-07-09 2023-02-28 Exosome Diagnostics, Inc. Methods for isolating microvesicles and extracting nucleic acids from biological samples
WO2018102162A1 (en) 2016-11-30 2018-06-07 Exosome Diagnostics, Inc. Methods and compositions to detect mutations in plasma using exosomal rna and cell free dna from non-small cell lung cancer patients

Also Published As

Publication number Publication date
AU2017366813B2 (en) 2023-04-20
CN110446790B (zh) 2023-03-31
EP3548635B1 (en) 2021-04-28
EP3548635A1 (en) 2019-10-09
JP2019536456A (ja) 2019-12-19
CN110446790A (zh) 2019-11-12
JP7280823B2 (ja) 2023-05-24
WO2018102162A1 (en) 2018-06-07
AU2017366813A1 (en) 2019-06-13
US20190376128A1 (en) 2019-12-12
US11427864B2 (en) 2022-08-30

Similar Documents

Publication Publication Date Title
EP3548635B1 (en) Methods to detect mutations in plasma using exosomal rna and cell free dna from non-small cell lung cancer patients
US20190093172A1 (en) Plasma-based detection of anaplastic lymphoma kinase (alk) nucleic acids and alk fusion transcripts and uses thereof in diagnosis and treatment of cancer
US12139766B2 (en) Methods and kits comprising gene signatures for stratifying breast cancer patients
US10636512B2 (en) Immuno-oncology applications using next generation sequencing
KR102080161B1 (ko) 개인 맞춤형 의료를 위한 유전자 패널, 그를 구성하는 방법, 및 그를 이용한 개인 맞춤형 치료 방법
US20190360051A1 (en) Swarm intelligence-enhanced diagnosis and therapy selection for cancer using tumor- educated platelets
US20180371550A1 (en) Loss of transcriptional fidelity leads to immunotherapy resistance in cancers
WO2019008412A1 (en) USE OF BLOOD GENE EXPRESSION ANALYSIS FOR CANCER CARE
US20230112964A1 (en) Assessment of melanoma therapy response
WO2019008415A1 (en) EXOSOMED AND PBMC GENE EXPRESSION ANALYSIS FOR CANCER CARE
WO2019008414A1 (en) GENE EXPRESSION ANALYSIS BASED ON EXOSOMES FOR THE CARE OF CANCER
WO2019014647A1 (en) IMMUNO-ONCOLOGIC APPLICATIONS USING NEXT GENERATION SEQUENCING
US20240218457A1 (en) Method for diagnosing active tuberculosis and progression to active tuberculosis
US20230143295A1 (en) Methods and kits for determining the risk of breast cancer recurrence
Ma Detecting Gene Modules Differentially Expressed in Multiple Human Brain Regions

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220928

EEER Examination request

Effective date: 20220928

EEER Examination request

Effective date: 20220928

EEER Examination request

Effective date: 20220928